Antifungal Drugs Market Expected to Reach $17,718 Million, By Top Competitors Analysis Pfizer Inc., Sanofi S.A., Gilead Sciences, Inc., Merck & Co., Inc, Novartis International AG, Abbott Laboratories, Bayer AG, Scynexis Inc.

Global Antifungal Drugs Market is expected to rise from $13,719 million in 2016 to $17,718 million by 2023. The industry is anticipated to register a CAGR of 3.7%, during the forecast period, 2017 - 2023. The antifungal drugs detect and eliminate fungal pathogens providing minimal side effect to the body. The fungal infection in the body is caused due to unhygienic and unclean environments wherein fungal agent thrive. These agents multiply by spreading spores that subsequently lead to infection on skin (superficial) or when inhaled (systemic)-fungal infections. The fungal infection leads to candidiasis, fungal pneumonia, mucormycosis, and other diseases. These infections are mostly non-lethal, but can result in death in rare cases.

Get PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/2370?utm_source=OPR

Antifungal drugs are medications that selectively eliminate fungal infections from the host. These fungal agents multiply by spreading spores that subsequently lead to infection on skin, hairs, vagina, and other body parts. The fungal infection causes candidiasis, fungal pneumonia, mucormycosis, and other diseases. The antifungal drugs market is continuously growing and evolving owing to robust developmental efforts made by researchers and market players in the field.

The growth in prevalence of fungal infection, rise in awareness levels pertaining to myriad fungal infections, and increase in demands of generic drugs are the major factors that drive the market growth. However, patent expiration of branded therapeutics and presence of counterfeit drugs restrain the growth of the antifungal drugs market. In addition, increase in R&D expenditure coupled with funding from the public & private sector is expected to provide lucrative growth opportunities to the antifungal drugs market.

The systemic antifungals segment is anticipated to maintain its dominance during the forecast period, accounting for about fifth-sevenths share of the global antifungal drugs market in 2016. This is due to the high usage of drugs such as azole for all the fungal indications and these also offer broad spectrum activity and improved safety levels. In addition, rise in prevalence of most commonly occurring systematic fungal infection such as candidiasis supplements the market growth. However, the superficial antifungals are expected to grow rapidly throughout the forecast period. This is because of the growth in incidence of hospital-acquired infections and increase in life expectancy among people.

The dermatophytosis indication is expected to register the highest CAGR of 4.1% throughout the forecast period. This is because of high incidences of skin infections in both children and adults. Candidiasis indication generated the highest revenue in 2016, accounting for about one-third of the total share in 2016, and is anticipated to maintain this trend from 2017 to 2023.

Get Customized Report @ https://www.alliedmarketresearch.com/request-for-customization/2370?utm_source=OPR

In 2016, Asia-Pacific and LAMEA collectively accounted for about three-eighths share of the market and is expected to continue this trend throughout the forecast period. Increase in awareness regarding antifungal drugs, availability of these drugs specifically in China, India, and the other developing economies, and growth in awareness regarding the fungal diseases drive the market. Moreover, the massive target population and growth in economy catering to the establishment of healthcare facilities boost the market.

The report provides a comprehensive analysis of the key players operating in the global antifungal drugs market such as

• Pfizer Inc.,
• Sanofi S.A.,
• Gilead Sciences, Inc.,
• Merck & Co., Inc.,
• Novartis International AG,
• Abbott Laboratories,
• Bayer AG,
• Scynexis Inc.,
• Enzon Pharmaceuticals, Inc., and
• GlaxoSmithKline Plc.

Table Of Content

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTER’S FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Increasing prevalence of fungal infection
3.6.1.2. Rising awareness levels pertaining to myriad fungal infections
3.6.1.3. Favorable government funds to combat the antifungal diseases

3.6.2. Restraints

3.6.2.1. Growing population with antifungal drug resistance
3.6.2.2. Presence of counterfeit drugs and side effects of antifungal drugs

3.6.3. Opportunities

3.6.3.1. Patent expirations and increasing funding from public & private organizations

Access Full Summery @ https://www.alliedmarketresearch.com/press-release/antifungal-drugs-market.html

About Us

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Allied Market Research provides one stop solution from the beginning of data collection to investment advice. The analysts at Allied Market Research dig out factors that help clients to understand the significance and impact of market dynamics. The company amplies client’s insight on the factors, such as strategies, future estimations, growth or fall forecasting, opportunity analysis, and consumer surveys among others. As follows, the company offers consistent business intelligent support to aid the clients to turn into prominent business firm.

Contact

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975
help@alliedmarketresearch.com
Web: www.alliedmarketresearch.com

This release was published on openPR.